jRCT2031250619招募中不适用
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants with Moderate to Severe Atopic Dermatitis
未提供0 个研究点目标入组 20 人开始时间: 待定
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
入排标准
- 年龄范围
- 18age old over 至 No limit（—）
- 性别
- All
入选标准
- •Participant must be aged greater than or equal (>= )18 years at the time of signing the informed consent
- •Participant has chronic atopic dermatitis (AtD) (according to American Academy of Dermatology Consensus Criteria) that has been present for at least >= 1 year prior to initiating the study (ie, signing of the informed consent form [ICF]) and with:
- •a. validated Investigator Global Assessment (vIGA) score >= 3 at Screening and Baseline
- •b. Eczema Area and Severity Index (EASI) score >= 16 at both Screening and Baseline
- •c. Peak Pruritus Numerical Rating Scale (PP-NRS) score of >= 4 at both Screening and Baseline
- •d. >= 10% body surface area (BSA) of AtD involvement at both Screening and Baseline
- •e. Documented recent history (within 6 months prior to Screening) of inadequate response to treatment with topical medications, or study participants for whom topical treatments are otherwise medically inadvisable (eg, due to important side effects or safety risks) and who are candidates for systemic therapy
排除标准
- •Participant has any history or presence of any medical or psychiatric condition, physical examination finding, laboratory test result, or electrocardiogram (ECG) signal that, in the opinion of the investigator, could constitute a risk when taking the study intervention; or interfere with the interpretation of data and could jeopardize or would compromise the ability of study participant to participate in this study
- •Active dermatologic conditions that may confound the diagnosis of AtD or would interfere with assessment of treatment, such as but not limited to scabies, seborrheic dermatitis, cutaneous lymphoma, ichthyosis, psoriasis, active allergic or irritant contact dermatitis
- •Presence or family history (first degree) of inflammatory bowel disease (includes Crohn disease and ulcerative colitis)
- •History of chronic or recurrent infections, or a serious or life-threatening infection within the 6 months prior to the Baseline (including herpes zoster) as judged by the investigator
- •Participants are not permitted to enroll into the study if they meet tuberculosis (TB) exclusion criteria
- •Previous treatment with galvokimig
- •Participant has relevant safety events to one or more interleukin (IL)-13 biologic response modifiers (ie, dupilumab, tralokinumab and lebrikizumab) that resulted in discontinuation and change of treatment
- •All systemic therapies (other than biologics), topical therapies and other treatments for AtD must be discontinued at least 4 weeks prior to Baseline
- •Treatment with biologic agents must discontinued at least 3 months prior to baseline
研究者
相似试验
招募中
不适用
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes (J3R-MC-YDAG)Obesity
OverweightjRCT20312508011,980
招募中
1 期
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of ATX3042024-514744-91-00Betagenon AB, Betagenon AB40
招募中
1 期
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Adaptive Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CLE-905-AG, a M1/M4 Muscarinic Agonist when administered alone or in conjunction with a Peripheral Muscarinic antagonist, in Healthy ParticipantsSchizophrenia2025-521914-25-00Clexio Biosciences Ltd.110
招募中
1 期
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability and Pharmacokinetic Study of Escalating Single and Multiple Doses of GTX-11 in Healthy SubjectsPulmonary fibrosis2023-504426-19-00Gat Therapeutics S.L.52
招募中
1 期
A Pilot, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Tolerability, Safety, and Pharmacokinetics of a Single Intra-articular Injection of CNTX-0066 in Participants with Chronic, Moderate-to-Severe Osteoarthritis Knee Pain2025-523737-26-00Centrexion Therapeutics Corp.20